{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:32:21Z","timestamp":1760239941558,"version":"build-2065373602"},"reference-count":71,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.hoc.2020.02.004","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T08:07:30Z","timestamp":1588666050000},"page":"673-687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Initial Treatment of High Tumor Burden Follicular Lymphoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Ciara L.","family":"Freeman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.hoc.2020.02.004_bib1","first-page":"441","article-title":"Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices","volume":"24","author":"Nooka","year":"2013"},{"issue":"suppl 5","key":"10.1016\/j.hoc.2020.02.004_bib2","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2020.02.004_bib3","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.1998.16.7.2332","article-title":"Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial","volume":"16","author":"Solal-Celigny","year":"1998","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2020.02.004_bib4","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2020.02.004_bib5","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.hoc.2020.02.004_bib6","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2020.02.004_bib7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2020.02.004_bib8","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/annonc\/mdh406","article-title":"Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression","volume":"15","author":"Montoto","year":"2004","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2020.02.004_bib9","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"issue":"9383","key":"10.1016\/j.hoc.2020.02.004_bib10","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"The Lancet"},{"issue":"14","key":"10.1016\/j.hoc.2020.02.004_bib11","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"issue":"9759","key":"10.1016\/j.hoc.2020.02.004_bib12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.hoc.2020.02.004_bib13","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2020.02.004_bib14","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","article-title":"Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma","volume":"23","author":"Schoder","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2020.02.004_bib15","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdn657","article-title":"The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)","volume":"20","author":"Noy","year":"2009","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2020.02.004_bib16","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1182\/blood-2018-99-116686","article-title":"Baseline suvmax did not predict histological transformation from follicular lymphoma to aggressive lymphoma in the phase III GALLIUM study","volume":"132","author":"Mir","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2020.02.004_bib17","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.sult.2010.10.001","article-title":"Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy","volume":"31","author":"Kinahan","year":"2010","journal-title":"Semin Ultrasound CT MR"},{"issue":"9","key":"10.1016\/j.hoc.2020.02.004_bib18","first-page":"1519","article-title":"Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study","volume":"45","author":"Boellaard","year":"2004","journal-title":"J Nucl Med"},{"issue":"30","key":"10.1016\/j.hoc.2020.02.004_bib19","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high\u2013tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1016\/j.hoc.2020.02.004_bib20","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.2017.74.1652","article-title":"Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma","volume":"36","author":"Luminari","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2020.02.004_bib21","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1200\/JCO.2017.35.15_suppl.7501","article-title":"Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: nine-year updated results from the StiL NHL1 study","volume":"35","author":"Rummel","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"9873","key":"10.1016\/j.hoc.2020.02.004_bib22","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.hoc.2020.02.004_bib23","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2020.02.004_bib24","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"33","key":"10.1016\/j.hoc.2020.02.004_bib25","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1200\/JCO.18.00262","article-title":"Chemotherapy-free initial treatment of advanced indolent lymphoma has durable effect with low toxicity: results from two nordic lymphoma group trials with more than 10 years of follow-up","volume":"36","author":"Lockmer","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"29","key":"10.1016\/j.hoc.2020.02.004_bib26","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.hoc.2020.02.004_bib27","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1016\/j.hoc.2020.02.004_bib28","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.hoc.2020.02.004_bib29","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2020.02.004_bib30","first-page":"1506","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013"},{"key":"10.1016\/j.hoc.2020.02.004_bib31","article-title":"First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4","author":"Walewski","year":"2019","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2020.02.004_bib32","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3109\/10428194.2014.953144","article-title":"Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States","volume":"56","author":"Nastoupil","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.hoc.2020.02.004_bib33","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","article-title":"Bendamustine: rebirth of an old drug","volume":"27","author":"Cheson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2020.02.004_bib34","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma with Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2020.02.004_bib35","first-page":"486","article-title":"Long term follow-up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 years","volume":"130","author":"Salles","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2020.02.004_bib36","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2020.02.004_bib37","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.004_bib38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/hon.44_2630","article-title":"Outcomes after early transformation (tPOD24) VS. early follicular lymphoma progression (fPOD24) in follicular lymphoma treated with frontline immunochemotherapy","volume":"37","author":"Maurer","year":"2019","journal-title":"Hematol Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2020.02.004_bib39","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study","volume":"33","author":"Casulo","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1016\/j.hoc.2020.02.004_bib40","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00277-016-2668-0","article-title":"Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin\u2019s lymphoma: evidence from a multicenter, retrospective study","volume":"95","author":"Mondello","year":"2016","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2020.02.004_bib41","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/bjh.15805","article-title":"Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population","volume":"185","author":"Magnano","year":"2019","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.hoc.2020.02.004_bib42","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.30795","article-title":"Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: a study report from the Spanish Lymphoma Oncology Group","volume":"123","author":"Provencio","year":"2017","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2020.02.004_bib43","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3324\/haematol.2017.186569","article-title":"Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi","volume":"103","author":"Storti","year":"2018","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.hoc.2020.02.004_bib44","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1200\/JCO.2018.79.3083","article-title":"Progress in advanced-stage follicular lymphoma","volume":"36","author":"Friedberg","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.hoc.2020.02.004_bib45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00277-017-3151-2","article-title":"Transformed follicular lymphoma","volume":"97","author":"Fischer","year":"2018","journal-title":"Ann Hematol"},{"issue":"32","key":"10.1016\/j.hoc.2020.02.004_bib46","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.hoc.2020.02.004_bib47","first-page":"2426","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007"},{"issue":"23","key":"10.1016\/j.hoc.2020.02.004_bib48","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety","volume":"36","author":"Hiddemann","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"14","key":"10.1016\/j.hoc.2020.02.004_bib49","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1056\/NEJMe1706154","article-title":"Which anti-CD20 antibody is better in follicular lymphoma?","volume":"377","author":"Armitage","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"22","key":"10.1016\/j.hoc.2020.02.004_bib50","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial","volume":"34","author":"Sarkozy","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2020.02.004_bib51","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3324\/haematol.2018.209015","article-title":"Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression","volume":"104","author":"Seymour","year":"2019","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2020.02.004_bib52","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1182\/blood-2018-99-118530","article-title":"Outcomes of follicular lymphoma patients treated with frontline bendamustine and rituximab: impact of histologic grade and early progression on overall survival","volume":"132","author":"Winter","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2020.02.004_bib53","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/annonc\/mdq574","article-title":"Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy","volume":"22","author":"Shustik","year":"2011","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2020.02.004_bib54","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdl039","article-title":"Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience","volume":"17","author":"Ganti","year":"2006","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2020.02.004_bib55","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1634\/theoncologist.2017-0037","article-title":"Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with follicular lymphoma Grade 3A: evidence from a multicenter, retrospective study","volume":"23","author":"Mondello","year":"2018","journal-title":"Oncologist"},{"issue":"26","key":"10.1016\/j.hoc.2020.02.004_bib56","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1016\/j.hoc.2020.02.004_bib57","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2020.02.004_bib58","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","article-title":"Prolonged clinical and molecular remission in patients with low-grade or follicular Non-Hodgkin's Lymphoma treated with Rituximab Plus CHOP chemotherapy: 9-year follow-up","volume":"22","author":"Czuczman","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.hoc.2020.02.004_bib59","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2020.02.004_bib60","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2020.02.004_bib61","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2020.02.004_bib62","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.15232","article-title":"A tale of two antibodies: obinutuzumab versus rituximab","volume":"182","author":"Freeman","year":"2018","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.hoc.2020.02.004_bib63","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1182\/blood.V128.22.613.613","article-title":"Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 GALLIUM study","volume":"128","author":"Pott","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2020.02.004_bib64","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.hoc.2020.02.004_bib66","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood-2018-10-879643","article-title":"Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy","volume":"134","author":"Zucca","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2020.02.004_bib67","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1182\/blood-2019-129422","article-title":"Results of a phase II study of obinutuzumab in combination with lenalidomide in previously untreated, high tumor burden follicular lymphoma (FL)","volume":"134","author":"Nastoupil","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2020.02.004_bib68","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","article-title":"Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies","volume":"1","author":"Trotman","year":"2014","journal-title":"The Lancet Haematology"},{"issue":"35","key":"10.1016\/j.hoc.2020.02.004_bib69","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","article-title":"Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS","volume":"30","author":"Dupuis","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2020.02.004_bib70","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"31","key":"10.1016\/j.hoc.2020.02.004_bib71","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","author":"Bachy","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2020.02.004_bib72","first-page":"1501","article-title":"Surveillance imaging during first-remission in follicular lymphoma does not impact overall survival","volume":"130","author":"Goldman","year":"2017","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:13:53Z","timestamp":1760184833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820300290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0889858820300290"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.02.004","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initial Treatment of High Tumor Burden Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}